Loading clinical trials...
Loading clinical trials...
Phase 1/2, Dose-Escalation Study to Evaluate the Safety and Immunogenicity of a DNA Vaccine, IMNN-101, Administered as a Single Dose in Healthy Adults Previously Vaccinated Against SARS-CoV-2
Conditions
Interventions
IMNN-101
Locations
2
United States
Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States
DM Clinical Research
Philadelphia, Pennsylvania, United States
Start Date
June 4, 2024
Primary Completion Date
March 7, 2025
Completion Date
March 7, 2025
Last Updated
July 23, 2025
NCT05359991
NCT07189936
NCT05421208
NCT05914649
NCT06435403
NCT05667597
Lead Sponsor
Imunon
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions